厄贝沙坦治疗轻中度原发性高血压的临床研究  

Clinical study of irbesartan in the treatment of mild and moderate essential hypertension

作　　者：林阳[1] 白树功[1] 朱小玲[1] 余振球[1] 李渝[1] 张文[1] 张娟[1] 韩智红[1] 刘文娴[1] 

机构地区：[1]首都医科大学附属北京安贞医院,北京100029

出　　处：《中国现代应用药学》2003年第6期517-519,共3页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的　评价国产厄贝沙坦治疗轻中度原发性高血压的有效性及安全性。方法　采用随机双盲平行对照的临床设计 ,将5 7例轻中度原发性高血压病患者分成试验组 (厄贝沙坦组 ) 2 7例和对照组 (缬沙坦组 ) 30例 ,起始剂量分别为 75mg·d-1和80mg·d-1,2周后如DBP仍≥ 90mmHg ,则加量至 15 0mg·d-1和 16 0mg·d-1,疗程 4周。结果　试验组与对照组血压均明显下降。试验组总有效率 86 .6 % ,不良反应发生率 7.4 %。对照组总有效率 93.3% ,不良反应发生率 10 .0 %。两组疗效和不良反应发生率均无显著性差异。结论　国产厄贝沙坦是一种安全有效的治疗轻、中度原发性高血压的药物 。OBJECTIVE To evaluate the clinical efficacy and safety of domestic irbesartan in the treatment of mild and moderate essential hypertension. METHOD A total of 57 patients with mild and moderate essential hypertension were enrolled in a randomized, double blind, control trial, irbesantan group 27 patients and valsartan group 30 patients. Patients were treated with 75～150mg·d -1 and 80～160mg·d -1 respectively, the dose regulation period was 2 weeks. RESULTS The blood pressure of patients in two groups decreased significantly after 4 weeks treatment. The total effective rates of irbesartan and valsartan group were 86.6% and 93.3% respectively, there was no significant difference between two groups.CONCLUSION Both domestic irbesartan and valsartan are effective and safe in the treatment of mild to moderate essential hypertension.

关 键 词：伊贝沙坦 缬沙坦 高血压 

分 类 号：R972.4[医药卫生—药品]